Clinical Trial Update: PSMA PET Registry (18F-DCFPyL) [NA]

View source ↗

Summary

This document reports the completion status of a PSMA PET imaging registry using the radiopharmaceutical 18F-DCFPyL for prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pylarify (piflufolastat F-18)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Carcinoma of Prostate | NA | Status: COMPLETED